Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: Three consecutive phase II trials

Carsten Rose, Lise Pedersen, Henning T. Mouridsen
In: European Journal of Cancer and Clinical Oncology · 1985 · vol. 21(10) , pp. 1171–1174 · doi:10.1016/0277-5379(85)90010-0 · PMID:2934258 · W2052704498
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

Malignant melanoma is generally considered as a hormone-independent tumour. However, epidemiological, clinical and experimental data suggest that steroid hormones can influence the growth of this tumour. The therapeutic efficacy of endocrine treatment was evaluated in three consecutive phase II trials with the anti-estrogen tamoxifen, the anti-androgen cyproterone acetate and the progestagen medroxyprogesterone acetate. The 53 evaluable patients were mainly untreated with other forms of systemic therapy. Using response criteria in accord with WHO, none of the patients in the three trials obtained an objective remission. In summary, the present trials have demonstrated that the clinical course of advanced malignant melanoma is indifferent to competitive and additive endocrine treatment.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (21)

Source provenance

openalex
last seen: 2026-05-10T10:41:41.225191+00:00
License: CC0 · commercial use OK